Document Detail

Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia.
MedLine Citation:
PMID:  9790377     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The purpose of this study was to investigate the safety of treating pre-eclampsia with magnesium sulfate, with clinical determinants used for drug discontinuation. STUDY DESIGN: One hundred sixty-eight patients were enrolled. After delivery, women with mild pre-eclampsia received a minimum of 6 hours of intravenous magnesium sulfate, whereas women with severe pre-eclampsia received a minimum of 12 hours. Magnesium sulfate was discontinued in the absence of clinical symptoms associated with spontaneous diuresis, minimal protein by urinary dipstick, and satisfaction of predetermined blood pressure criteria. RESULTS: Patients with mild pre-eclampsia required significantly less magnesium sulfate (mean 9.5 +/- 4.2 hours) than did those with severe pre-eclampsia alone (mean 16 +/- 5.9 hours); pre-eclampsia superimposed on chronic hypertension (mean 16 +/- 5.8 hours); or hemolysis, elevated liver enzyme, and low platelet count syndrome (mean 20 +/- 6.7 hours). With this protocol there was no eclampsia, and recovery room time was reduced by 50%. CONCLUSION: Individual determination of postpartum magnesium sulfate therapy for pre-eclampsia appears to be a safe approach that carries minimal risk of eclampsia.
M H Ascarelli; V Johnson; W L May; R W Martin; J N Martin
Related Documents :
21847647 - Chest compressions versus ventilation plus chest compressions: a randomized trial in a ...
11511137 - Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausa...
20410917 - Swedish hypertension open care retrospective study in men and women (show).
2344507 - Control of blood pressure in scotland: the rule of halves.
3988447 - The natural history of blood pressure in childhood.
10847197 - Heart rate and blood pressure variability in normal subjects compared with data from be...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  179     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1998-11-10     Completed Date:  1998-11-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  952-6     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cesarean Section
Chronic Disease
Cost-Benefit Analysis
Delivery, Obstetric
Gestational Age
Hypertension / complications
Liver / enzymology
Magnesium Sulfate / administration & dosage,  therapeutic use*
Postpartum Period
Pre-Eclampsia / drug therapy*,  economics
Time Factors
Reg. No./Substance:
7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Deve...
Next Document:  Success rate of cytogenetic analysis at the time of second-trimester dilation and evacuation.